Principal Financial Group Inc. Trims Position in Hologic, Inc. (HOLX)

Principal Financial Group Inc. cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 399,047 shares of the medical equipment provider’s stock after selling 9,359 shares during the period. Principal Financial Group Inc. owned approximately 0.14% of Hologic worth $16,401,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Prudential Financial Inc. lifted its holdings in shares of Hologic by 0.5% in the 3rd quarter. Prudential Financial Inc. now owns 300,094 shares of the medical equipment provider’s stock worth $12,298,000 after purchasing an additional 1,530 shares during the last quarter. MML Investors Services LLC bought a new stake in shares of Hologic in the 3rd quarter worth approximately $247,000. Martingale Asset Management L P bought a new stake in shares of Hologic in the 3rd quarter worth approximately $2,796,000. BlackRock Inc. lifted its holdings in shares of Hologic by 0.9% in the 3rd quarter. BlackRock Inc. now owns 18,773,720 shares of the medical equipment provider’s stock worth $769,349,000 after purchasing an additional 164,937 shares during the last quarter. Finally, American International Group Inc. lifted its holdings in shares of Hologic by 4.9% in the 3rd quarter. American International Group Inc. now owns 110,131 shares of the medical equipment provider’s stock worth $4,513,000 after purchasing an additional 5,170 shares during the last quarter. 89.91% of the stock is owned by institutional investors.

In other news, insider Benjamin Jordan Cohn sold 6,830 shares of Hologic stock in a transaction on Monday, March 11th. The stock was sold at an average price of $46.70, for a total transaction of $318,961.00. Following the transaction, the insider now directly owns 22,002 shares in the company, valued at approximately $1,027,493.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Peter J. Valenti III sold 4,242 shares of Hologic stock in a transaction on Friday, March 1st. The shares were sold at an average price of $47.38, for a total value of $200,985.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,378 shares of company stock worth $1,105,836. 0.90% of the stock is owned by insiders.

Several brokerages recently issued reports on HOLX. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a report on Tuesday. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a report on Tuesday. ValuEngine downgraded Hologic from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Hologic in a report on Tuesday, April 2nd. Finally, TheStreet upgraded Hologic from a “c” rating to a “b” rating in a research report on Monday, March 4th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have issued a buy rating to the company’s stock. Hologic presently has a consensus rating of “Hold” and an average target price of $44.62.

HOLX traded up $0.47 during trading hours on Wednesday, hitting $44.73. The company’s stock had a trading volume of 1,166,276 shares, compared to its average volume of 1,898,432. Hologic, Inc. has a fifty-two week low of $35.10 and a fifty-two week high of $48.82. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.30 and a quick ratio of 0.91. The stock has a market cap of $12.59 billion, a P/E ratio of 20.06, a P/E/G ratio of 2.04 and a beta of 0.75.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, January 30th. The medical equipment provider reported $0.58 EPS for the quarter, beating the consensus estimate of $0.57 by $0.01. Hologic had a positive return on equity of 25.59% and a negative net margin of 12.88%. The firm had revenue of $830.70 million for the quarter, compared to analysts’ expectations of $823.22 million. During the same period last year, the firm earned $0.55 EPS. The firm’s revenue was up 5.0% compared to the same quarter last year. Equities analysts anticipate that Hologic, Inc. will post 2.41 EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/principal-financial-group-inc-has-16-40-million-holdings-in-hologic-inc-holx.html.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: Calculate Your Return on Investment (ROI)

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.